Free Trial
NASDAQ:SAVA

Cassava Sciences Q4 2024 Earnings Report

Cassava Sciences logo
$1.44 +0.04 (+2.86%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.35%)
As of 04/17/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 3, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Cassava Sciences' Q1 2025 earnings is scheduled for Friday, May 9, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cassava Sciences Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:SAVA), a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

View Cassava Sciences Profile

More Earnings Resources from MarketBeat